Skip to main content
news
A Takeda logo is seen in its research hub in Cambridge, Massachusetts, U.S., November 26, 2018. REUTERS/Julie Steenhuysen

Cleary Gottlieb Steen & Hamilton has advised Japanese pharmaceutical giant Takeda on its planned acquisition of U.S.-based Nimbus Therapeutics' experimental psoriasis drug, with Goodwin Procter acting for the seller.

The deal value is expected to be up to $6 billion, reported Reuters. It added that the drug, codenamed "NDI-034858", has shown statistically significant reduction in moderate-to-severe psoriasis in a mid-stage study and is expected to enter late-stage trials next year.

The Goodwin team was led by partners Bill Collins, Sarah Solomon and Yasin Akbari in Boston, and Erini Svokos in New York.

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

CAM, AZB, SAM, Latham advise on landmark $1.3 bln Swiggy IPO

by Nimitt Dixit |

Cyril Amarchand Mangaldas is advising SoftBank-backed Indian food and grocery delivery giant Swiggy on its much-anticipated initial public offering worth $1.3 billion, with AZB & Partners and Latham & Watkins advising the bookrunning lead managers.

Wadia Ghandy, CAM guide StanChart’s $490 mln sale of personal loan business

by Nimitt Dixit |

Wadia Ghandy has guided Kotak Mahindra on its acquisition of Standard Chartered Bank’s personal loan business in India for $490 million, with Cyril Amarchand Mangaldas advising Standard Chartered.

AZB, S&R act on $645 mln Afcons IPO

by Nimitt Dixit |

AZB & Partners is advising Afcons, one of India’s largest international infrastructure construction companies, on its upcoming initial public offering worth $645 million. S&R Associates is acting for the bookrunning lead managers.